Aclaris Therapeutics, Inc. (ACRS)
ACRS Stock Price Chart
Explore Aclaris Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ACRS price movements and trends.
ACRS Company Profile
Discover essential business fundamentals and corporate details for Aclaris Therapeutics, Inc. (ACRS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Oct 2015
Employees
61.00
Website
https://www.aclaristx.comCEO
Neal S. Walker
Description
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
ACRS Financial Timeline
Browse a chronological timeline of Aclaris Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.16, while revenue estimate is $1.38m.
Earnings released on 7 May 2026
EPS came in at -$0.15 surpassing the estimated -$0.16 by +6.25%, while revenue for the quarter reached $2.00m , beating expectations by +51.02%.
Earnings released on 26 Feb 2026
EPS came in at -$0.16 falling short of the estimated -$0.15 by -6.67%, while revenue for the quarter reached $1.30m , missing expectations by -37.47%.
Earnings released on 6 Nov 2025
EPS came in at -$0.12 surpassing the estimated -$0.13 by +7.69%, while revenue for the quarter reached $3.30m , beating expectations by +59.29%.
Earnings released on 7 Aug 2025
EPS came in at -$0.13 matching the estimated -$0.13, while revenue for the quarter reached $1.78m , beating expectations by +56.22%.
Earnings released on 8 May 2025
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%, while revenue for the quarter reached $1.46m , missing expectations by -59.01%.
Earnings released on 27 Feb 2025
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $9.21m , beating expectations by +30.82%.
Earnings released on 6 Nov 2024
EPS came in at -$0.11 falling short of the estimated -$0.08 by -37.50%, while revenue for the quarter reached $4.35m , beating expectations by +105.00%.
Earnings released on 7 Aug 2024
EPS came in at -$0.15 surpassing the estimated -$0.19 by +21.05%, while revenue for the quarter reached $2.77m , beating expectations by +51.98%.
Earnings released on 7 May 2024
EPS came in at -$0.24 surpassing the estimated -$0.28 by +14.29%, while revenue for the quarter reached $2.40m , beating expectations by +75.04%.
Earnings released on 27 Feb 2024
EPS came in at -$0.30 surpassing the estimated -$0.37 by +18.92%, while revenue for the quarter reached $17.57m , beating expectations by +422.92%.
Earnings released on 6 Nov 2023
EPS came in at -$0.41 surpassing the estimated -$0.48 by +14.58%, while revenue for the quarter reached $9.28m , beating expectations by +491.21%.
Earnings released on 7 Aug 2023
EPS came in at -$0.42 surpassing the estimated -$0.45 by +6.67%, while revenue for the quarter reached $1.87m , missing expectations by -1.63%.
Earnings released on 8 May 2023
EPS came in at -$0.42 surpassing the estimated -$0.44 by +4.55%, while revenue for the quarter reached $2.53m , beating expectations by +44.46%.
Earnings released on 23 Feb 2023
EPS came in at -$0.41 surpassing the estimated -$0.46 by +10.87%, while revenue for the quarter reached $7.75m , beating expectations by +288.82%.
Earnings released on 8 Nov 2022
EPS came in at -$0.30 surpassing the estimated -$0.39 by +23.08%, while revenue for the quarter reached $19.02m , beating expectations by +1.09k%.
Earnings released on 3 Aug 2022
EPS came in at -$0.31 surpassing the estimated -$0.36 by +13.89%, while revenue for the quarter reached $1.53m , missing expectations by -5.20%.
Earnings released on 10 May 2022
EPS came in at -$0.31 surpassing the estimated -$0.39 by +20.51%, while revenue for the quarter reached $1.45m , missing expectations by -9.10%.
Earnings released on 24 Feb 2022
EPS came in at -$0.37 falling short of the estimated -$0.36 by -2.78%, while revenue for the quarter reached $1.50m , missing expectations by -16.20%.
Earnings released on 2 Nov 2021
EPS came in at -$0.35 falling short of the estimated -$0.27 by -29.63%, while revenue for the quarter reached $1.66m , missing expectations by -6.27%.
Earnings released on 5 Aug 2021
EPS came in at -$0.34 falling short of the estimated -$0.26 by -30.77%, while revenue for the quarter reached $1.82m , beating expectations by +4.23%.
ACRS Stock Performance
Access detailed ACRS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
